linjc16/ctgov huggingface dataset:
A New Method for Estimating Dynamic Intrinsic PEEP

Study Overview
=================
Brief Summary
-----------------
Dinamic intrinsic PEEP is

Detailed Description
-----------------
Dynamic intrinsic positive end-expiratory pressure (PEEPi dyn) play an important pathophysiology role in many acute respiratory pathologies. The most accurate method to quantify PEEPi dyn is to measure the rise in transdiaphragmatic pressure (Pdi) at end expiration at the point of the contraction of the inspiratory muscles until inspiratory flow starts. Such method, however, is invasive, poor comfortable and require patient active collaboration. The purpose of this study is describe a new non-invasive method for estimate PEEPi dyn and validate this method with gold-standard-one.

Official Title
-----------------
A New Method for Estimating Dynamic Positive End-expiratory Pressure. Description and Validation With PEEPi Dyn Measured With Transdiaphragmatic Pressure

Conditions
-----------------
PEEP, Intrinsic, PEEP, Occult, Respiratory Insufficiency

Intervention / Treatment
-----------------
* Device: diaphragm ecography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute or chronic respiratory failure Age >=18 y Exclusion Criteria: Lack of informed consent Controindication to the placement of oesophageal and gastric catheter: esophageal varices, gastric or oesophageal bleeding in the previous 30 days, gastric or oesophageal surgery in the preceding year. Cardiac arrest Severe emodinamic instability (> 1 vasoacttive drug) Acute coronary syndrome (AMI/UA) Inability to protect airway Respiratory arrest Pregnancy suspected or confirmed Diaphragm palsy Curarization in the preceding five hours Mechanical ventilation in controlled mode.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: diaphragm ecography|recording of diaphragm ecography|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation and agreement between AutoPEEP recorded with the transdiaphragmatic pressure (Pdi) vs ecography measurements. |  | 20 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation and agreement between neural inspiratory time and ecographic inspiratory time |  | 10 minutes | 
| Inter-rater agreement to assest method reliability |  | 10 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dynamic intrinsic PEEP, diaphragm echography, respiratory mechanics
Comparison Between Resin Based and Glass Ionomer Based Hydrophilic Fissure Sealants

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to clinically evaluate the retention and caries formation of hydrophilic fissure sealants among adolescents after one year.

Official Title
-----------------
One Year Clinical Comparison Between Resin Based and Glass Ionomer Based Hydrophilic Fissure Sealants Among Adolescents: A Randomized Clinical Trial

Conditions
-----------------
Caries

Intervention / Treatment
-----------------
* Procedure: Sealing deep pits and fissures


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have existing pits and fissures that are anatomically deep and caries susceptible. Healthy patients with no history of previous systematic diseases that can affect their oral health and sealant application. Cooperative patients who will allow the clinical applications Exclusion Criteria: Uncooperative behaviour limiting the use of sealants throughout the procedure. Patients with history of medical diseases, drug therapies or any other serious relevant problem. Patients with well coalesced pits and fissures Patients allergic to sealant material Patients who underwent orthodontic treatment.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Resin based sealant (Ultraseal XT Hydro)<br> | Procedure: Sealing deep pits and fissures<br>* Application of the pit and fissure sealant<br>|
| Active Comparator: Glass ionomer based sealant (Fugi Triage)<br> | Procedure: Sealing deep pits and fissures<br>* Application of the pit and fissure sealant<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retention rate | Full retention (FR): The material is fully present on the occlusal surfaces Partially lost (PL): The material is present, but as a result of either wear or loss of the material, part of the previously sealed fissure, was exposed. Totally lost (TL): No trace of the material to be detected on the surface | Change from baseline at 3, 6, 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Caries formation | Decayed: If the explorer caught on the tooth after insertion into the fissures | Change from baseline at 3, 6, 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pit and fissure sealant, Retention rate, Caries formation, Hydrophilic sealant
Evaluation of Respiratory Specimens for Bacterial and Viral Pathogens by Real-Time PCR

Study Overview
=================
Brief Summary
-----------------
Community acquired pneumonia(CAP) is a common cause of morbidity and mortality. The diagnosis of CAP from the microbiology perspective has been challenging. Recent reports suggest the utility of real-time PCR for rapid and accurate diagnoses of these pathogens. Real-Time PCR tests, using the LightCycler instrument, will be performed on excess or additional specimens after extraction of nucleic acid.

Detailed Description
-----------------
Excess patient specimens normally collected for routine microbiologic testing for CAP and in some cases additional specimens (i.e.,blood, urine, throat swab) will be evaluated using real-time PCR tests developed in our laboratory. Specimens will be performed on patients suspect for CAP. Test will be directed at variety of pathogens including but not limited to M.pneumoniae, C. pneumoniae, Legionella pneumophila, Streptococcus pneumoniae, B. pertussis, influenza viruses, adenovirus, and metapneumovirus. The ultimate goal is to have a panel of highly accurate and rapid (same day) tests that can be orderable and performed in short period time for CAP cases. Real-Time PCR tests, using the LightCycler instrument, will be performed on excess or additional specimens after extraction of nucleic acid. Real-time PCR tests, using the LightCycler instrument, will be performed on excess or additional specimens after extraction nucleic acid. These tests will include the organisms listed above. As nucleic acid extracts will be archived, other pathogens can be tested in the future should we develop additional real-time PCR tests. All results obtained by real-time PCR will be compared to results for conventional testing as listed above. Sensitivity, specificity and predictive values will be calculated. In cases where discordant results occur, additional PCR testing and or medical history review will be conducted.

Official Title
-----------------
Evaluation of Respiratory Specimens for Bacterial and Viral Pathogens by Real-Time PCR

Conditions
-----------------
Cough, Fever

Participation Criteria
=================
Eligibility Criteria
-----------------
Greater than 18 years of age. Cough present greater than one day and a history of fever and chills or documented fever in the Emergency Department

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Magnetic Resonance Imaging (MRI) of Brain Iron in Neurodegenerative Disease

Study Overview
=================
Brief Summary
-----------------
Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis are recognized as a major health concern at the present time. There is information in magnetic resonance imaging (MRI) studies regarding the role of brain iron in normal brain aging that may be enhanced with the use of better scanning equipment and procedures, and by correlating this information with clinical data. This research study aims to develop and evaluate a number of techniques that can potentially improve the effectiveness of three tesla (3T) magnetic resonance imaging of neurodegenerative brain disorders.

Detailed Description
-----------------
Eligibility: A healthy person without memory complaints or someone with neurodegenerative disease. However, the person should not have metal in the body (ie, pacemaker, implants, shrapnel, etc.), should not be pregnant, and should not have claustrophobic anxieties. Study Procedures: During a regular office visit, a neurologist will perform a routine physical and neurological examination, including your medical and family history, to determine your eligibility for this study. You will then be scheduled for a series of neuropsychological tests, which take between 1 to 1.5 hours, and an MRI scan, which takes approximately 1 hour to complete. This is a longitudinal study and you may be asked to repeat these procedures approximately every six months for the duration of this 2 year project.

Official Title
-----------------
High Field MRI of Brain Iron in Neurodegenerative Disease

Conditions
-----------------
Neurodegenerative Diseases, Mild Cognitive Impairment

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years or older Healthy person without memory complaints OR person diagnosed with a neurodegenerative disease (ie, Alzheimer's disease, Parkinson's disease, multiple sclerosis) Exclusion Criteria: MR contraindication such as metal in body (ie, pacemaker, implant, shrapnel, etc.) Pregnant Claustrophobic anxieties

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
3T MRI, neurodegenerative disease, Alzheimer's disease, spectroscopy, Normal, healthy subject without memory complaint, Not pregnant, MR compatible
Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma

Study Overview
=================
Brief Summary
-----------------
This study will assess further the safety and tolerability of long-term treatment with omalizumab by extending omalizumab treatment by 1 year for those patients with allergic asthma who successfully completed study CIGE25011E2.

Official Title
-----------------
An Open-label Extension Study to Assess Long Term Safety and Tolerability of Omalizumab Treatment in Adults and Adolescents With Severe Allergic Asthma Who Participated in the 52 Week CIGE250011E2 Study

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: Omalizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a history of severe allergic asthma who completed the treatment period of CIGE250011E3 protocol, without experiencing any significant drug-related adverse events Male or female patients 12-75 years of age who have given written informed consent approved by the ethical committee Exclusion Criteria: Patients who had not received study medication for greater than 84 days since visit 38 of study CIGE240011E3 Pregnant females or nursing mothers Patients with know hypersensitivity to any ingredients of Omalizumab or related drugs Other protocol-defined inclusion/exclusion criteria may apply

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Omalizumab|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety assessed by adverse events, serious adverse events, hematology, blood chemistry and urinalysis value, vital signs data, the performance of physical examinations and body weight measurements. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy assessed by changes in forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), the investigator's assessment of asthma control, corticosteroid use, the incidence of hospitalization and outpatients visits, and absenteeism fr |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, anti-immunoglobulin E, omalizumab, allergic asthma
Effects of Perioperative Intravenous Dexamethasone on Pain in Out Patient Knee Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine the opiate sparing effects of intravenously administered dexamethasone in outpatient knee surgery. Dexamethasone is a glucocorticoid with well known antiemetic effects. However, the analgesic effects of dexamethasone have not been adequately researched. Following surgery, patients are typically discharged home with PO opiates to manage post-operative pain. The investigators believe that by using VAS (Visual Analog Scale) for Pain the investigators can show that a single dose of dexamethasone can reduce pain scales and opiate consumption post-operatively, on Post Operative Day (POD 1) when compared to placebo.

Detailed Description
-----------------
Findings of Modest improvement in pain scores and postoperative nausea at 24 hours with Dexamethasone

Official Title
-----------------
Effects of Perioperative Intravenous Dexamethasone on Pain in Out Patient Knee Surgery

Conditions
-----------------
Post Operative Pain, Nausea

Intervention / Treatment
-----------------
* Drug: Dexamethasone 8mg iv x1
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients undergoing ambulatory knee arthroscopy surgery Must provide phone contact number and agree to phone followup on post operative day 1 Exclusion Criteria: Patients with major systemic disease Allergy or intolerance to study drug

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Intervention<br>Dexamethasone 8mg iv x 1 | Drug: Dexamethasone 8mg iv x1<br>* Dexamethasone 8mg iv x1<br>|
| Placebo Comparator: Placebo<br>placebo | Drug: placebo<br>* 2 ml normal saline IV x1<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post Operative VAS Pain Scale | Patients were instructed to select a number between zero and ten to indicate the degree of pain they experience (zero being no pain and ten being the worst pain they could imagine). Therefore, ten is worse than zero. | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amount of Postop Narcotic Usage | Patients were requested to record the number of prescribed oral analgesic (oxycodone 5 mg/aceteminophen 325 mg) tablets taken for the first 24 hours following discharge | 24 hours | 
| Postop Nausea | NRS scale 0-10 for nausea. Zero indicates no nausea, Ten indicates the worst nausea imagined. | 24 hours |
Deep Brain Stimulation for Patients With Parkinson's Disease.

Study Overview
=================
Brief Summary
-----------------
Deep brain stimulation of the sub thalamic nucleus (STN-DBS) is an efficient treatment to improve motor and non motor signs of Parkinson's disease (PD). In people aged more 70 years, an increased rate of side effects such as post-operative cognitive decline and/or postural instability with falls has been suspected with less improvement in the quality of life. Here, Investigators aim further explore the effects of STN-DBS in 50 patients with PD people aged more 69 years in a randomized parallel controlled study.

Detailed Description
-----------------
The effects of combined bilateral deep brain stimulation of the subthalamic nucleus and medical treatment on the quality of life will be evaluated in 25 PD patients aged more 69 years in comparison to 25 PD patients aged more 69 years that only received medical drug treatment.

Official Title
-----------------
Effets de la Stimulation cérébrale Profonde Chez Les Patients âgés Avec Maladie de Parkinson : Essai contrôlé randomisé Multicentrique

Conditions
-----------------
Parkinson Disease

Intervention / Treatment
-----------------
* Device: Stimulation of the subthalamic nucleus


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Parkinson's disease disease duration > 5 years levodopa related motor complications dopasensitivity > 50% signed informed written consent medical social insurance Exclusion Criteria: dementia contra-indication to neurosurgery

Ages Eligible for Study
-----------------
Minimum Age: 69 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Stimulation of the subthalamic nucleus<br>25 patients with Parkinson's disease | Device: Stimulation of the subthalamic nucleus<br>* Stimulation of the subthalamic nucleus<br>|
| Best medical treatment<br>25 patients with Parkinson's disease | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life | PDQ-39 scale | Quality of life one year after surgery |
Safety Surveillance of Targeted Drugs for Pulmonary Hypertension Using a Computerized Follow-up System: a Nationwide Cohort Study

Study Overview
=================
Brief Summary
-----------------
Recruit at least 700 PH patients, follow up every 6 months based on a computerized follow-up system. Primary outcomes are adverse drug events and all-cause death.

Official Title
-----------------
Safety Surveillance of Targeted Drugs for Pulmonary Hypertension Using a Computerized Follow-up System: a Nationwide Cohort Study

Conditions
-----------------
Pulmonary Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age from 3 months to 85 years, no sex preference; Right heart catheter meet the following conditions simultaneously: mPAP≥25mmHg, and PVR > 3 Wood units(in children PVRi > 3 WU x m2), and PAWP≤15 mmHg at rest; Patients diagnosed with group 1,2,4,5 PH according to the WHO classification, detailed description is as follows: Pulmonary arterial hypertension, Lung disease / chronic hypoxia associated pulmonary hypertension, Pulmonary hypertension associated with pulmonary artery stenosis / obstruction and Pulmonary hypertension caused by other multiple factors Take at least one pulmonary hypertension targeted drug or calcium antagonist; Signed written informed consent. Exclusion Criteria: Patients diagnosed with pulmonary hypertension related to left heart disease;

Ages Eligible for Study
-----------------
Minimum Age: 3 Months
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse drug events |  | through study completion, an average of 6 months | 
| All-cause Mortality |  | through study completion, an average of 6 months |